On Mar. 31, 2020, Cue Health announced that is had been awarded up to $30 million in base funding and options from the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA) to accelerate the development and regulatory validation of an over-the-counter and professional use Influenza and Multiplex Respiratory Pathogen diagnostic cartridges for the Cue Health Monitoring System.

The funding was awarded by BARDA, part of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services. The funding enabled Cue to accelerate the development and validation of its molecular COVID-19 test, paving the way for its scale-up to facilitate on-the-ground management of this pandemic cycle and prepare for similar infectious disease outbreaks in the future.

The Cue Health Monitoring System enables a range of in-home and in-clinic diagnostics. The system uses a highly portable reader system to test clinical samples in a disposable test cartridge and sends the results to a connected mobile application. The Cue Influenza test cartridge, which is undergoing clinical validation is designed to detect Influenza A and B.